AstraZeneca's Brilinta faces another six month wait at FDA
This article was originally published in Scrip
Executive Summary
Potential US approval of AstraZeneca’s ticagrelor (Brilinta) has been pushed back to the summer after the FDA categorised the company’s recent response as a class 2 resubmission. This gives a six-month review cycle and a new PDUFA date of 20 July.